ENA Respiratory

ENA Respiratory is a clinical-stage pharmaceutical company headquartered in Melbourne, Australia, with operations in the USA. The company focuses on developing first-in-class, small molecule prophylactics to prevent complications from respiratory viral infections. Their lead product, INNA-051, is a nasal dry powder designed for weekly self-administration, aiming to enhance the body's natural defense mechanisms against various respiratory viruses. ENA Respiratory has received support from investors such as Brandon Capital, The Minderoo Foundation, Uniseed, and Flu Lab, and has established partnerships with organizations like the U.